

Defective NTHL1 truncation mutants do not bind formamidopyrimidine (FapyA)

Doetsch, PW., Kuiper, RP., Orlic-Milacic, M., Rivera Polo, B., de Voer, RM.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of <u>Creative Commons Attribution 4.0 International (CC BY 4.0)</u>
<u>License</u>. For more information see our <u>license</u>.

30/04/2024

https://reactome.org

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142.
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467.
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res, 46*, D649-D655.
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology, 14*, e1005968.

Reactome database release: 88

This document contains 1 reaction (see Table of Contents)

https://reactome.org Page 2


Defective NTHL1 truncation mutants do not bind formamidopyrimidine (FapyA)

Stable identifier: R-HSA-9630044

Type: transition

Compartments: nucleoplasm

Diseases: cancer



NTHL1 Q90TER (NTHL1 Q90*) truncation mutant (Weren et al. 2015) lacks the DNA binding domain and the glycosylase domain and is thus predicted to be unable to recognize and bind damaged DNA, including damaged DNA containing formamidopyrimidine (FapyA), although this has not been experimentally tested. NTHL1 Q287TER (NTHL1 Q287*) truncation mutant (Broderick et al. 2017) lacks a portion of the DNA binding domain, including glutamine residue Q287, important for substrate recognition (Robey-Bond et al. 2017) and is predicted to be unable to recognize and bind damaged DNA, including damaged DNA containing formamidopyrimidine (FapyA), although this has not been experimentally tested.

Literature references

Broderick, P., Kinnersley, B., Tomlinson, I., Dobbins, SE., Chubb, D., Houlston, RS. et al. (2017). Validation of Recently Proposed Colorectal Cancer Susceptibility Gene Variants in an Analysis of Families and Patients-a Systematic Review. *Gastroenterology*, 152, 75-77.e4.

Editions

2018-12-13	Authored	Orlic-Milacic, M.
2019-01-14	Reviewed	Kuiper, RP.
2019-01-17	Edited	Orlic-Milacic, M.
2019-01-31	Reviewed	Doetsch, PW.
2019-02-19	Reviewed	Rivera Polo, B.
2019-02-21	Reviewed	de Voer, RM.